Active Studies

Clinical trials into the therapeutic applications of cannabinoids are ongoing both in Canada and Internationally. This section contains grouped lists of active relevant clinical trials as of May 8, 2014. Accessed at: http://www.clinicaltrials.gov/ct2/results?term=cannabinoids&pg=1

Intervention Disease Imaging
Cannabidiol Cancer All imaging studies
Cannabis Diabetes / Diet Geographical Distribution of Trials:
Dronabinol HIV /AIDS
Endocannabinoids IBD
Nabilone Multiple Sclerosis
Nabiximols Pain
Rimonabant Mental Health
Synthetic / Novel Cannabinoids Addiction
THC Schizophrenia / Psychosis
  Other

Clinical trials grouped by the disease targeted:

Cancer
A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours Recruiting  e-Therapeutics PLC
Sativex for Treatment of Chemotherapy Induced Neuropathic Pain Completed  CDHA
Orexigenic Therapy With Delta-9-Tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study Completed Alberta
Opioid and Cannabinoid Pharmacokinetic Interactions Completed  NIDA
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting Terminated Veeda
Diabetes/Diet
A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes Recruiting GW Pharma
GWMD1092 - GW42003 : GW42004 Together Plus Alone in Type II Diabetes Completed GW Pharma
Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque Completed  AUTH
Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome Unknown  Cornell
Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics Unknown  UdeM
The Effects of Rimonabant, on Weight and Metabolic Risk Factors Terminated  Maryland
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise Terminated  Sanofi
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-Diabetic Drug Terminated  Sanofi
Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS) Terminated  Sanofi
HIV/AIDS
Combination of an Investigational Cannabinoid and Methadone for HIV-Associated Neuropathy Terminated  UW
Inflammatory Bowel Disease
Cannabis for Inflammatory Bowel Disease Unknown  Meir
Combined THC and CBD Drops for Treatment of Crohn's Disease Recruiting  Meir
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome (IBS) Completed  Mayo
Multiple Sclerosis / Spasticity
An Observational Post-Marketing Safety Registry of Sativex Recruiting GW Pharma
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) Beginning  Hadassah
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity (NS-MSS) Completed  Almirall SA
Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease (CANALS) Recruiting  U Padova
Cannabis for Spasticity in Multiple Sclerosis Recruiting  UCDavis
Use of Cannabinoids in Patients With Multiple Sclerosis Unknown Rome
Novel Immune Markers in Patients With Multiple Sclerosis (NIMMS) Unknown UW
MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study Terminated  IKFE
Pain
Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease (Cannabis-SCD) Beginning UCSF
Delta-THC in Pain in Dementia Beginning  Radboud
The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Recruiting  U Iowa
Cannabinoid Modulation of Pain Recruiting  Yale
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors Recruiting  UTex HSC
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors Recruiting Texas
Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons Recruiting  Manitoba
Sativex for Treatment of Chemotherapy Induced Neuropathic Pain Recruiting  CDHA
A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia Completed Manitoba
Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia Completed McGill
Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain Completed Heidelberg
Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (Delta-pain) Completed  Radboud
Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain Completed Boston
A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain Completed  GW Pharma
Nabilone for the Treatment of Phantom Limb Pain Completed Manitoba
Opioid and Cannabinoid Pharmacokinetic Interactions Completed  UCSF, NIDA
Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain Completed Heidelberg
Paracetamol CSF Pharmacokinetics Study Completed Barts
Characterization of the Analgesic Effects of Oral THC and Smoked Marijuana in Non-Treatment Seeking Marijuana Smokers Completed  NIDA
Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain Unknown Calgary
Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients Unknown Toronto
Efficacy of Dronabinol for the Treatment of Cervical Dystonia Unknown  Toronto
Mental Health
Cannabinoid Control of Fear Extinction Neural Circuits in PTSD Beginning  Michigan
Delta-THC in Pain in Dementia Recruiting  Radboud
The Effects of ∆-9-THC and Naloxone in Humans Recruiting  Yale
The Effects of Cannabidiol and ∆-9-THC in Humans Recruiting Yale
Effects of Delta-9-THC and Iomazenil in Healthy Humans Recruiting Yale
Cannabinoids and Cerebellar-Motor Functioning Recruiting  Yale
Cannabinoids, Neural Synchrony, and Information Processing Recruiting Yale, NIDA
Cannabinoid Augmentation of Fear Response in Humans Recruiting Yale
Add on Study on delta 9- THC Treatment for Posttraumatic Stress Disorders (PTSD) Ongoing  Hadassah
Cannabinoids in Bipolar Affective Disorder Ongoing UBC
Marinol in Trichotillomania or Obsessive Compulsive Disorder Completed  UMN
Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed  Odense
Addiction
A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users Beginning  INSYS
Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment (ACCENT) Recruiting MedU SC, NIDA
Behavioral Effects of Tiagabine and Cannabis Recruiting U Kentucky
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence Recruiting NIMH
Cannabinoid Receptor Function & Alcoholism Recruiting Yale
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal Recruiting Yale
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia (DCCS) Recruiting Mclean Hospital
Exercise as a Treatment for Substance Use Disorders Protocol Ongoing  U Texas SW Medical Center
Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis Completed  NIDA
Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation Completed NIDA
Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment Completed Konstanz
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse Completed  NYPsych
Antagonist-Elicited Cannabis Withdrawal Completed  NIDA
Rimonabant to Reduce Alcohol Consumption Completed  NIAAA
Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE) Completed  Sanofi
Abuse Potential of Sativex Completed  GW Pharma
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana Unknown  MUSC
Schizophrenia / Psychosis
Cannabis, Schizophrenia, and Reward: Self-Medication and Agonist Treatment Beginning  Dartmouth-Hitchcock MC
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder Recruiting GW Pharma
A four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients Beginning CIMHM
Probing the Cannabinoid System in Individuals with a Family History of Psychosis Recruiting  Yale
Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia Unknown  Shalvata
Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis Recruiting Yale
Cannabinoids, Neural Synchrony, and Information Processing Recruiting Yale
Imaging Cannabinoid CB1 Receptors in Schizophrenia Recruiting NIMH
Effects of Delta-9-THC and Iomazenil in Healthy Humans Recruiting Yale
The Effects of Cannabidiol and ∆-9-THC in Humans Recruiting  Yale
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia Completed  Yale
A Clinical Trial on the Antipsychotic Properties of Cannabidiol Completed  Cologne
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis Completed  Cologne
Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment Completed Konstanz
Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia Completed Jena
Efficacy and Safety of AVE1625 as a co-Treatment With Antipsychotic Therapy in Schizophrenia Terminated   Sanofi
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes Terminated UColorado
Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics Unknown  UdeM
Other
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation Recruiting  Rabin
Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation Recruiting  Rabin
Neuroprotection by Cannabinoids in Huntington's Disease Ongoing  GW Pharma
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis Completed  Shionogi

 

Return to Main Active Studies Listing